Skip to main content

[@RenaissancePeriodization] The First FDA Approved Muscle Growth Drug Is Here! Here’s the Catch.

· 4 min read
[@RenaissancePeriodization] Summarizer
[@RenaissancePeriodization] Summarizer
Video Bot

@RenaissancePeriodization - "The First FDA Approved Muscle Growth Drug Is Here! Here’s the Catch."

Link: https://youtu.be/HuEQ0hEWI7Y

Duration: 12 min

Transcript: Download plain text

Short Summary​

The FDA approved apitegromab, the first myostatin inhibitor, a monoclonal antibody developed by Scholar Rock, though the episode emphasizes it is currently impractical for fitness enthusiasts. In trials, a low dose preserved 4 lb more muscle over 24 weeks when combined with weight-loss drugs, and bimagrumab plus tirzepatide cut lean mass loss by 55% without blocking fat loss. The host predicts cheaper, more accessible myostatin inhibitors will arrive within 3–5 years, potentially transforming both public health and gym culture.

Key Quotes​

  1. "Holy crap, will it be a big [music] deal? Bye-bye steroids for pretty much everybody." (00:00:00)
  2. "It costs like a trillion dollars a year." (00:00:24)
  3. "Guys, the FDA just approved for general prescription to the public the first myostatin inhibitor drug and you would think this would make us radically excited." (00:00:34)
  4. "Switched completely off, it can unleash pro bodybuilder level muscle growth in all skeletal muscles in your body without training." (00:02:06)
  5. "at its current price, it's estimated to cost something like $350,000 a year to administrate." (00:09:12)

Detailed Summary​

FDA Approval of Apitegromab​

  • The FDA approved apitegromab for general public prescription, marking the first myostatin inhibitor drug on the market.
  • Apitegromab is a monoclonal antibody developed by Scholar Rock that works by inhibiting myostatin, a protein that normally suppresses skeletal muscle growth to preserve metabolism for organs like the liver, kidneys, heart, and brain during starvation.

Muscle Preservation Trial Data​

  • In trials, a low dose of apitegromab preserved 4 lb more muscle when combined with powerful weight-loss drugs over 24 weeks.
  • A separate study showed the tirzepatide-alone group lost about 7.6 lb of lean mass, while tirzepatide plus bimagrumab lost only 3.4 lb of muscle, a 55% reduction in lean mass loss.
  • Bimagrumab plus tirzepatide users also lost roughly 1 lb more fat than tirzepatide alone, indicating the drug does not interfere with fat loss.
  • In people with severe muscle disease, bimagrumab improved both muscle mass and physical function, producing real, functional muscle.

Why It's Impractical Right Now​

  • Apitegromab requires in-hospital IV infusion every several weeks or months and cannot be obtained through gray-market channels, pharmacies, or fake prescriptions.
  • For off-label fitness use, a doctor would have to prescribe 10 times the approved dose every two weeks instead of every two months, an unrealistic protocol.
  • The estimated cost is around $350,000 per year to administer, even at therapeutic (non-bodybuilder) doses, far more expensive than anabolic steroids, which the host notes grow comparable muscle for far less.
  • The host predicts the price will drop to tens of thousands per year within one year, and to an affordable level in two to three years, but not soon enough for recreational use.

Natural Myostatin-Deficient Examples​

  • Natural cases include a mouse with myostatin blocked, a greyhound with no functional myostatin gene, myostatin-negative cows, and human babies born without functioning myostatin, which occurs in roughly one out of a billion births.

Future Drug Pipeline​

  • The desired formulations are an at-home injectable like bimagrumab (reconstituted from a vial and injected twice a week) or an oral small-molecule pill.
  • Multiple companies are working on these next-generation myostatin inhibitors, with expected market release in 3 to 5 years at competitive prices.
  • The host predicts women could get jacked with zero androgenic effects (no facial hair or voice deepening), and adoption would spread like Ozempic and tirzepatide.
  • Public health could see a massive boost because GLP-1 users lose muscle along with fat, and myostatin inhibitors could preserve it, though overall gym attendance may drop while hardcore gym culture surges.
  • RP plans to update listeners when these drugs enter the pipeline or reach the market.